Published in J Biol Chem on September 16, 1994
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer (2012) 2.35
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A (1995) 2.10
Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A (2004) 1.82
Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal (2009) 1.79
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov (2011) 1.57
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood (2009) 1.29
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest (2007) 1.22
Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis. Leukemia (2008) 1.20
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Emerging roles for crk in human cancer. Genes Cancer (2010) 1.09
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol (1998) 1.09
Profiling the global tyrosine phosphorylation state by Src homology 2 domain binding. Proc Natl Acad Sci U S A (2001) 1.06
Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase. Mol Cell Biol (1999) 1.01
The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene (2010) 0.98
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood (2005) 0.94
Models of crk adaptor proteins in cancer. Genes Cancer (2012) 0.94
Apoptotic regulation by the Crk adapter protein mediated by interactions with Wee1 and Crm1/exportin. Mol Cell Biol (2002) 0.93
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene (2013) 0.91
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. Nat Protoc (2014) 0.88
Rho GTPases in hematopoietic stem cell functions. Curr Opin Hematol (2009) 0.87
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia. J Cancer Res Clin Oncol (2003) 0.83
LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells. Invest New Drugs (2010) 0.83
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem (2014) 0.82
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica (2010) 0.81
The adaptor protein Crk in immune response. Immunol Cell Biol (2013) 0.81
MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia. Oncotarget (2016) 0.81
Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. Haematologica (2012) 0.80
C3G forms complexes with Bcr-Abl and p38α MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion. Cell Commun Signal (2013) 0.78
Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL. PLoS One (2015) 0.77
Binding Mechanism of the N-Terminal SH3 Domain of CrkII and Proline-Rich Motifs in cAbl. Biophys J (2016) 0.76
Oncogenic Signaling Adaptor Proteins. J Genet Genomics (2015) 0.75
Crk-like adapter protein is overexpressed in cervical carcinoma, facilitates proliferation, invasion and chemoresistance, and regulates Src and Akt signaling. Oncol Lett (2016) 0.75
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate. Oncotarget (2016) 0.75
Drug conjugated nanoparticles activated by cancer cell specific mRNA. Oncotarget (2016) 0.75
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther (2000) 5.09
THE DISTRIBUTION IN THE HUMAN BODY OF SPIROCHAETA ICTEROHAEMORRHAGIAE. J Exp Med (1917) 4.80
Evaluation of smoking prohibition policy in a health maintenance organization. Am J Public Health (1986) 4.08
Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension (2001) 4.07
Presence of an SH2 domain in the actin-binding protein tensin. Science (1991) 4.03
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet (2000) 3.82
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Propensity of ectopic liver to hepatocarcinogenesis: case reports and a review of the literature. Hepatology (1999) 3.29
Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer (1983) 3.28
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 3.26
Granulocyte colony-stimulating factor and its receptor. Blood (1991) 3.24
Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med (1996) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Nonsurgical, percutaneous transhepatic cholangiography--diagnostic significance in medical problems of the liver. Am J Dig Dis (1974) 3.09
Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol (1991) 3.05
Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nat Genet (2001) 2.85
Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol (1996) 2.81
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med (1996) 2.68
cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science (1990) 2.59
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci (2000) 2.57
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol (1994) 2.55
Characterization of genes in the cellulose-synthesizing operon (acs operon) of Acetobacter xylinum: implications for cellulose crystallization. J Bacteriol (1994) 2.49
Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest (1988) 2.46
Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J Immunol (1986) 2.45
Characterization of an antigen expressed by human natural killer cells. J Immunol (1983) 2.44
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood (1999) 2.43
NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol (1994) 2.40
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 2.37
A CONTRIBUTION TO THE ETIOLOGY AND PATHOLOGY OF RAT-BITE FEVER. J Exp Med (1917) 2.36
Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen. Cell (1982) 2.35
Haemagglutinating activity of Bacteroides melaninogenicus. Arch Oral Biol (1974) 2.35
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood (1991) 2.35
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest (1981) 2.34
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
Percutaneous transhepatic drainage of the biliary tract: technique and results in 104 cases. Gastroenterology (1978) 2.27
Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology (1988) 2.26
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem (1993) 2.23
STI571: targeting BCR-ABL as therapy for CML. Oncologist (2001) 2.15
The long-term pathological evolution of chronic hepatitis C. Hepatology (1996) 2.15
Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology (1985) 2.11
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 1.98
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol (1993) 1.98
The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A (1992) 1.94
Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology (1985) 1.92
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res (1984) 1.85
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer (2009) 1.85
Histopathology of membranous obstruction of the inferior vena cava in the Budd-Chiari syndrome. Gastroenterology (1992) 1.85
Purification and properties of hemagglutinin from culture supernatant of Bacteroides gingivalis. Infect Immun (1986) 1.85
Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A (1993) 1.84
Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord (1993) 1.82
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J (1995) 1.78
Chronic myelogenous leukemia. Curr Opin Oncol (2001) 1.78
Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology (1986) 1.76
Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature (1991) 1.76
Protein kinase activity associated with simian virus 40 T antigen. Proc Natl Acad Sci U S A (1979) 1.72
Measurements of the molecular size of the simian virus 40 large T antigen. J Virol (1978) 1.70
The intervention research process in occupational safety and health: an overview from the National Occupational Research Agenda Intervention Effectiveness Research team. J Occup Environ Med (2001) 1.69
Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood (2000) 1.64
CIRCULATING IMMUNITY PRINCIPLES IN RAT-BITE FEVER. J Exp Med (1917) 1.64
Chronic myeloid leukemia: current treatment options. Blood (2001) 1.62
Early recognition of hepatocellular carcinoma. Hepatology (1986) 1.62
Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A (1990) 1.57
Gross anatomic features of hepatocellular carcinoma from three disparate geographic areas. Proposal of new classification. Cancer (1984) 1.57
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci U S A (1994) 1.55
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia (2004) 1.54
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol (1989) 1.54
Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. J Gastroenterol Hepatol (1999) 1.54
Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood (1986) 1.53
Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol (1988) 1.53
Expression of cytokines after meniscal rasping to promote meniscal healing. Arthroscopy (2001) 1.53
Protein tyrosine kinases and cancer. Biochim Biophys Acta (1997) 1.52
Structural gene and complete amino acid sequence of Pseudomonas aeruginosa IFO 3455 elastase. J Bacteriol (1989) 1.51
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 1.51
Expression of the M-CSF (CSF-1) gene by human monocytes. Blood (1987) 1.49
Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer (1977) 1.49
Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol (1997) 1.48
Relative frequencies of portosystemic pathways and renal shunt formation through the "posterior" gastric vein: portographic study in 460 patients. Hepatology (1990) 1.48
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 1.47
Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XI. Pseudogenetic restrictions of hybridoma suppressor factors. J Exp Med (1981) 1.46
Salivary bisphenol-A levels detected by ELISA after restoration with composite resin. J Mater Sci Mater Med (2005) 1.45
Conservation of myeloid surface antigens on primate granulocytes. Blood (1983) 1.44
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood (2000) 1.44
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem (1999) 1.44
Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol (1995) 1.44
Changing incidence of hepatocellular carcinoma in Japan. Cancer Res (1987) 1.44
Rat liver cholesterol 7 alpha-hydroxylase. Pretranslational regulation for circadian rhythm. J Biol Chem (1990) 1.43
Characterization of the Treponema denticola prtP gene encoding a prolyl-phenylalanine-specific protease (dentilisin). Infect Immun (1996) 1.43
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet (1988) 1.43